New combo treatment aims to boost Cancer-Killing power of CAR-T therapy
NCT ID NCT07478848
Summary
This early-stage study is testing whether giving a short course of targeted radiation therapy along with an oral antibiotic (vancomycin) is safe and feasible for patients with aggressive B-cell lymphomas before they receive standard CAR-T cell therapy. The goal is to see if this 'bridging' approach can help prepare the body and potentially improve the effectiveness of the CAR-T treatment. The study will enroll about 14 adults who are already scheduled to receive CAR-T therapy for their lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.